<DOC>
	<DOC>NCT00191009</DOC>
	<brief_summary>This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.</brief_summary>
	<brief_title>Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Patient presents with Alzheimer's Disease based on clinical history. Patient must have a Mini Mental Status Score between 10 and 26. Patient must have a reliable caregiver in frequent or daily contact with the patient. Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months. Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease. Patients who have a history in the past 5 years or any current evidence of major psychiatric illness. Patients who have narrow angle glaucoma. Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>